Most Favored Nation drug pricing would import harmful foreign pricing policies—putting patient access and America’s innovation leadership at risk.
A flawed policy known as Most Favored Nation (MFN) drug pricing would tie U.S. drug prices to prices set by foreign countries. That might sound like a simple solution—but it isn’t guaranteed to lower costs for patients and comes with serious risks:
This isn’t just about policy—it’s about people. Foreign price setting puts future cures at risk by discouraging investment in U.S. research and development. For patients and families hoping for the next breakthrough, that delay could be life-changing—or life-threatening.
“Bringing that approach here would make it less likely that new mental health medications would ever reach the market. That would be a step backward when breakthroughs are bridging a new offer of hope.”
— Jennifer, Nurse & Patient Advocate
There are smarter, immediate ways to lower drug costs without importing flawed policies.
Tell Congress: Support real solutions that lower costs for patients today, not foreign price controls
